$0.28
11.17% today
NYSE, Apr 04, 08:40 pm CET
ISIN
US2941001024
Symbol
ENZ
Sector
Industry

Enzo Biochem, Inc. Stock price

$0.32
-0.17 34.32% 1M
-0.81 71.81% 6M
-0.40 55.40% YTD
-0.94 74.71% 1Y
-2.65 89.27% 3Y
-2.13 87.00% 5Y
-2.69 89.42% 10Y
NYSE, Closing price Thu, Apr 03 2025
-0.01 4.18%
ISIN
US2941001024
Symbol
ENZ
Sector
Industry

Key metrics

Market capitalization $16.70m
Enterprise Value $-20.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.30
EV/Sales (TTM) EV/Sales -0.70
P/S ratio (TTM) P/S ratio 0.57
P/B ratio (TTM) P/B ratio 0.36
Revenue (TTM) Revenue $29.10m
EBIT (operating result TTM) EBIT $-8.33m
Free Cash Flow (TTM) Free Cash Flow $-15.75m
Cash position $40.30m
EPS (TTM) EPS $-0.41
Short interest 0.67%
Show more

Is Enzo Biochem, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Enzo Biochem, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Enzo Biochem, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Enzo Biochem, Inc.:

Buy
100%

Financial data from Enzo Biochem, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jan '25
+/-
%
29 29
59% 59%
100%
- Direct Costs 16 16
73% 73%
55%
13 13
20% 20%
45%
- Selling and Administrative Expenses 18 18
59% 59%
61%
- Research and Development Expense 2.25 2.25
50% 50%
8%
-6.95 -6.95
81% 81%
-24%
- Depreciation and Amortization 1.38 1.38
50% 50%
5%
EBIT (Operating Income) EBIT -8.33 -8.33
79% 79%
-29%
Net Profit -21 -21
53% 53%
-73%

In millions USD.

Don't miss a Thing! We will send you all news about Enzo Biochem, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enzo Biochem, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE”) and to have its common stock quoted on the OTCQX Best Market (“OTCQX”).
Neutral
GlobeNewsWire
18 days ago
FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss.
Neutral
GlobeNewsWire
3 months ago
FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) its 30 trading-day average market capitalization was less than $50 million and its last rep...
More Enzo Biochem, Inc. News

Company Profile

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Head office United States
CEO Kara Cannon
Employees 136
Founded 1976
Website www.enzo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today